ID 635 -
Kwas eikozapentaenowy
PL: Kwas eikozapentaenowy
EN: Eicosapentaenoic acid (EPA)
Pdf: eicosapentaenoic acid
Oświadczenie (2)
- niepożądanych utrata masy ciała
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is eicosapentaenoic acid (EPA).
EPA is a 20-carbon fatty acid with 5 double bonds of the omega 3 series (omega-3 long-chain polyunsaturated fatty acid). It is a well recognised nutrient naturally present in foods from animal sources, especially oily fish, or used, generally in the form of triglycerides, for addition to foods or food supplements. EPA is measurable in foods by established methods.
The Panel considers that the food constituent, eicosapentaenoic acid (EPA), which is the subject of the health claims is sufficiently characterised.
2.4. Wzrost apetytu po niezamierzonej utracie masy ciała prowadzący do zwiększenia ilości przyjmowanej energii (ID 635)
The claimed effect is “undesirable weight loss”. The Panel assumes that the target population is underweight individuals willing to increase their energy intake.
In the context of the proposed wording, the Panel assumes that the claimed effect refers to the increase in appetite after an episode of unintentional weight loss.
The Panel considers that an increase in appetite after unintentional weight loss leading to an increase in energy intake, if sustained, might be a beneficial physiological effect.
3.4. Wzrost apetytu po niezamierzonej utracie masy ciała prowadzący do zwiększenia ilości przyjmowanej energii (ID 635)
Ten references including three narrative reviews on the therapeutic management of wasting syndromes, four human studies and three animal studies have been provided to substantiate the claim.
Some of the human studies were conducted in patients with cancer-induced cachexia. The Panel considers that the evidence provided does not establish that severely ill patients with cancer-induced cachexia are representative of the target population with respect to the claimed effect. Also, two open label case reports on the effects of EPA on body weight in patients with severe anorexia nervosa were provided. The Panel considers that no conclusions can be drawn from these uncontrolled studies for the scientific substantiation of the claimed effect.
The Panel also considers that the evidence provided in the animal studies is not sufficient to predict the occurrence of an effect of EPA intake in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of EPA and a sustained increase in appetite after unintentional weight loss leading to an increase in energy intake.
Warunki i możliwe ograniczenia stosowania oświadczenia
At least 1-2 g EPA/day